Clinical Status, Treatment, and Disease Burden of Generalised Myasthenia Gravis in the Asia–Pacific
Across the Asia-Pacific, most patients did not achieve pharmacological remission despite prescribed treatments, and experienced treatment-related AEs, indicating significant unmet clinical needs. It is suggested that corticosteroid overreliance in maintenance treatment could be associated with increases in comorbidities and AEs. Further research is needed to understand how novel treatments could impact clinical outcomes and reduce corticosteroid reliance for patients with gMG in the Asia-Pacific.
Authors
- Clare Ringland
- Sophie Barlow (ORCID: https://orcid.org/0000-0001-5604-1360)
- Tom Webb (ORCID: https://orcid.org/0000-0002-4625-4052)
- Gregor Gibson
- Bolam Lee
- Yoon‐Ho Hong (ORCID: https://orcid.org/0000-0002-3325-6358)
- Mami Kasahara‐Kiritani (ORCID: https://orcid.org/0000-0003-0170-1442)
- Niall Hatchell (ORCID: https://orcid.org/0000-0002-8432-6379)
- Keira Joann Herr (ORCID: https://orcid.org/0000-0003-1322-6407)
- Shiva Lauretta Birija
- Dae Young Yu (ORCID: https://orcid.org/0000-0003-1091-5792)
- Hannah Connolly
- Joe Conyers
Institutions
- Johnson & Johnson (United States) (US)
- Adelphi Group (United Kingdom) (GB)
- SNUH SMG-SNU Boramae Medical Center (KR)
- Johnson & Johnson (Singapore) (SG)
- Johnson & Johnson (Brazil) (BR)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1007/s40120-025-00845-4
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00